Clinical Trials Sponsored by Parc Taulí

Total 2448 results

Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Hemophilia A or B With Inhibitors

Croatia, North Macedonia, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
UNICANCER
Novartis; Fondation ARC

Completed

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (SAFIR-TOR)

Metastatic Breast Cancer

France
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Torsemide Tablets Under Fed Conditions

Healthy
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Universitat Autonoma de Barcelona
Hospital Son Espases; Parc Sanitari Sant Joan de Déu; Andaluz Health Service; Hospital... and other collaborators

Recruiting

Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders (CR+MCTp)

Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Brief Psychotic Disorder

Spain
Corporacion Parc Tauli
Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital; Hospital Arnau... and other collaborators

Unknown

Respiratory Microbiome and COPD Exacerbations (RESMECOPD) (RESMECOPD)

Pulmonary Disease, Chronic Obstructive | Exacerbation COPD

Spain
Fundació Sant Joan de Déu
Parc Sanitari Sant Joan de Déu

Recruiting

Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients

Psychosis | Emotional Dysfunction

Spain
Parc de Salut Mar
Ministerio de Sanidad, Servicios Sociales e Igualdad

Completed

Interaction Between a Natural Aldehyde Dehydrogenase 2 (ALDH2) Inhibitor and Alcohol (COCADEP/2)

Healthy

Spain
ARC Medical Devices Inc.

Completed

Discrete(TM) Safety Clinical Trial GLAD-01

Safety and Tolerability in Healthy Volunteers

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Torsemide Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions
Park Medical centrum
Erasmus Medical Center

Recruiting

The Spine PROMCO Study (Spine PROMCO)

Lumbar Disc Herniation | Spinal Stenosis | Spondylolisthesis

Netherlands
Infervision
University of Maryland, College Park

Not yet recruiting

Performance Study for InferRead CT Pneumonia.AI

Pneumonia
Seung-Jung Park

Recruiting

Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)

Coronary Artery Disease

Korea, Republic of
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Roswell Park Cancer Institute
Lumeda,Inc.

Active, not recruiting

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Malignant Mesothelioma | Non-Small Cell Lung Carcinoma | Pleural Disorder

United States
Orange Park Medical Center
410 Medical

Completed

Orange Park Out-of-Hospital Quality Improvement Study for Improving CMS Sepsis Core Measures

Sepsis | Shock, Septic | Fluid Therapy | Emergency Medical Services | Quality Improvement

United States
McMaster University
West Park Healthcare Centre

Completed

Home Balance Pilot for Fall Reduction in COPD

Pulmonary Disease, Chronic Obstructive

Canada
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Baxalta now part of Shire

Terminated

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Hemophilia B

Turkey, Spain
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Hemophilia A

United States
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Terminated

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

Sickle Cell Disease

United Kingdom
Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
Baxalta now part of Shire

Completed

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Poland, Germany, Taiwan, Israel, Ukraine, United Kingdom, Malaysia, Japan, Austria, Switzerland, Sweden, Bulgaria, Lithuania, Romania
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Baxalta now part of Shire

Terminated

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Acquired Hemophilia A

United States, Canada, India, United Kingdom
Baxalta now part of Shire

Terminated

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Lymphoma | Leukemia | Graft Versus Host Disease

United States, Australia
Baxalta now part of Shire

Completed

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

Malignant Solid Tumors | Metastatic Adenocarcinoma of the Colon or Rectum

Germany, United States
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Baxalta now part of Shire

Completed

Phase 1 Dosing Study of BAX 513 in Healthy Volunteers

Healthy Volunteers

Austria
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Baxalta now part of Shire

Completed

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Hemophilia A | Congenital Factor VIII (FVIII) Deficiency

United Kingdom, France, Germany, Hungary
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
Baxalta now part of Shire

Terminated

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

United States
Fundacion para la Salud Materno Infantil

Terminated

Position at Birth,Placental Transfusion Volume and Cord Clamping

Delay Cord Clamping | Placental Trasfusion

Argentina

Clinical Trials Sponsored by Parc Taulí

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations